Updated on 3 September 2026
Organ on chips, organoids and other NAMs for biomedical research
Business Development Manager, PharmD, MPH at Leitat Technological Center
Barcelona, Spain
About
-
Organ-on-chip contribution:
• Design, prototype ad upscale microfluidics/organ-on-chip devices using tailored matrices and hydrogels, cell types, and configurable architectures that support organ-level development and function.
• Adding gravitational and pressurized perfusion systems to create different levels of complexity.
• Sensing integration, detection of surveillance, anticipation of events, correction of processes in culture, can be added to improve the design.
• Our platforms enable the generation of both healthy and pathological models to evaluate drug safety and efficacy across multiple organs and diseases. We have colorectal cancer model, liver, lung and gut, but are open to consider development of different organs /indications.
• The models can be more personalized with cell monitoring, viability and cytotoxicity assessment, TEER permeability. They can also be coupled with advanced detection of cell markers, ECM components, ions, pH, metabolites, and cytokines.
• Finally, we can create digital-twin technologies of the organ on chip system
• We can use robotics to automate the platform and manipulate the hydrogels. This way we can think about a standardised platform more aligned with future regulations. -
Organoids and 2D models:
We can also develop various in vitro models from iPSCs, such as:
• 3D organoid cultures (we can also consider other indications): Corneal, Intestinal, Brain, Pancreatic, Lung
• 2D cultures (since we can differentiate iPSCs into the three germ layers, we could also consider differentiating them into other relevant cell types): Motor neurons, Cardiomyocytes, Hepatocytes, Pancreatic cells -
Bioreactors and biosensors for in vitro models
-
Bioprinted tissue constructs
-
Virtual Twins
-
Advanced in vitro model muscle contraction (patented technology)
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
Patient-specific iPSC biobanking for disease modeling and precision medicine
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Arsen Arakelyan
Director, Head of Human Genomics Lab at Institute of Molecular Biology
Yerevan, Armenia
Project cooperation
Multi-omics integration in genome-scale metabolic models
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Egils Stalidzans
Tenured professor at Rīga Stradiņš University
Riga, Latvia
Project cooperation
Mechanistic mathematical modeling (systems biology approach)
- Partner seeks Consortium/Coordinator
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Egils Stalidzans
Tenured professor at Rīga Stradiņš University
Riga, Latvia